Pertubation With Lignocaine in Endometriosis (PLEASE)
Pertubation With Lignocaine in Endometriosis Associated Symptoms Effect Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 118 72
- Läkargruppen Victoria Söderhallarna 120
-
Stockholm, Sweden, 141 86
- Karolinska Institute, Fertility Unit, K59 Karolinska University Hospital at Huddinge
-
Stockholm, Sweden, 182 88
- Department of Gynaecology and Obstetrics Danderyd Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 20 years
- endometriosis verified by laparoscopy
- dysmenorrhea or pelvic pain defined as a pain-score of >50 mm (VAS)
- normal Fallopian tubes
- regular menstrual cycles 21-35 days
- treatment with oral contraceptives (OC) ongoing > 1 month and continued during the trial
- previous hormonal treatment discontinued > 1 month (OC, gestagens) and > 6 months (GnRH)
- no wish for pregnancy during the study
- normal Pap-smear
- negative Chlamydia-test
- negative pregnancy-test
- informed consent given and signed
Exclusion Criteria:
- Continuous treatment with medication that may increase risk for infection - clinical signs of pelvic inflammatory disease
- hyperreactivity to local anesthesia
- fibroids > 2 cm
- ongoing treatment with GnRH-analog
- ongoing continuous treatment with high dose gestagens
- pregnancy
- peritubal adhesions
- occluded Fallopian tubes
- inability to understand information or comply with the study procedures
- participation in a clinical study within one year before the present study
- any disease or laboratory finding considered of importance by the investigator not to include the patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pertubation with Endole® (lignocaine)
Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
|
Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
Other Names:
|
|
Placebo Comparator: Placebo
Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
|
Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain-questionnaire (validated for endometriosis) supplemented with VAS-scale.
Time Frame: After three pertubations
|
The pain-questionnaire will be filled out: first time during the first period after inclusion in the study (1st menstruation prior to study treatments=baseline for evaluation) and thereafter during 2nd, 3rd, 4 th, 7th, 10th and 13th menstrual periods.
|
After three pertubations
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life-questionnaire (validated), EHP-30
Time Frame: At the 7th menstruation i.e. after approximately 6 months.
|
The Quality of life-questionnaire will be filled out: first time during the first period after inclusion in the study (1st menstruation prior to study treatment=baseline for evaluation) and thereafter during 7th and 13th menstrual period.
|
At the 7th menstruation i.e. after approximately 6 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Karin Wickström, MD, Danderyd Hospital, SE-182 88 Stockholm, Sweden
- Study Director: Greta Edelstam, MD, Karolinska University Hospital at Huddinge SE-141 86 Stockholm, Sweden
Publications and helpful links
General Publications
- Wickstrom K, Edelstam G. Minimal clinically important difference for pain on the VAS scale and the relation to quality of life in women with endometriosis. Sex Reprod Healthc. 2017 Oct;13:35-40. doi: 10.1016/j.srhc.2017.05.004. Epub 2017 May 25.
- Wickstrom K, Spira J, Edelstam G. Serum concentration of lignocaine after pertubation: an observational study. Drugs R D. 2013 Sep;13(3):235-9. doi: 10.1007/s40268-013-0022-8.
- Wickstrom K, Bruse C, Sjosten A, Spira J, Edelstam G. Pertubation with lignocaine as a new treatment of dysmenorrhea due to endometriosis: a randomized controlled trial. Hum Reprod. 2012 Mar;27(3):695-701. doi: 10.1093/humrep/der434. Epub 2012 Jan 9.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Pain
- Neurologic Manifestations
- Menstruation Disturbances
- Pelvic Pain
- Endometriosis
- Dysmenorrhea
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
Other Study ID Numbers
- ISI-06-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.